Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10079877rdf:typepubmed:Citationlld:pubmed
pubmed-article:10079877lifeskim:mentionsumls-concept:C0042776lld:lifeskim
pubmed-article:10079877lifeskim:mentionsumls-concept:C0206679lld:lifeskim
pubmed-article:10079877lifeskim:mentionsumls-concept:C0205725lld:lifeskim
pubmed-article:10079877lifeskim:mentionsumls-concept:C0019704lld:lifeskim
pubmed-article:10079877lifeskim:mentionsumls-concept:C0220806lld:lifeskim
pubmed-article:10079877lifeskim:mentionsumls-concept:C0038720lld:lifeskim
pubmed-article:10079877lifeskim:mentionsumls-concept:C1264633lld:lifeskim
pubmed-article:10079877lifeskim:mentionsumls-concept:C0060967lld:lifeskim
pubmed-article:10079877pubmed:issue1lld:pubmed
pubmed-article:10079877pubmed:dateCreated1999-5-17lld:pubmed
pubmed-article:10079877pubmed:abstractTextA series of chemically oversulphated galactosaminoglycans (SO3H:COOH ratio > or = 2) were tested in vitro as antiviral agents against human immunodeficiency virus type 1 (HIV-1), the aetiological agent of AIDS, and against herpes simplex virus type 1 and human cytomegalovirus, two agents responsible for opportunistic infections in HIV-infected people. The oversulphated derivatives displayed an increase in activity ranging from one to four orders of magnitude against the three viruses, as compared to the natural parent compounds (SO3H:COOH, ratio approx. 1). The antiviral activity of these polyanions appears to be favoured by a high degree of sulphation and a high molecular mass. An oversulphated dermatan, with a SO3H:COOH ratio of 2.86 and molecular mass of 23.2 kDa, was the most potent anti-HIV-1 compound (EC50 0.04 microgram/ml). A second oversulphated dermatan, with a SO3H:COOH ratio of 2.40 and molecular mass of 25 kDa, displayed the highest activity against HSV-1 (EC50 0.01 microgram/ml). An oversulphated chondroitin, with a SO3H:COOH ratio of 2.80 and molecular mass of 17.3 kDa, was the strongest anti-HCMV agent (EC50 0.4 microgram/ml). In view of the absence of the side-effects typical of heparin-like compounds, a combination of these derivatives could have therapeutic potential.lld:pubmed
pubmed-article:10079877pubmed:languageenglld:pubmed
pubmed-article:10079877pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10079877pubmed:citationSubsetIMlld:pubmed
pubmed-article:10079877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10079877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10079877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10079877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10079877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10079877pubmed:statusMEDLINElld:pubmed
pubmed-article:10079877pubmed:monthJanlld:pubmed
pubmed-article:10079877pubmed:issn0956-3202lld:pubmed
pubmed-article:10079877pubmed:authorpubmed-author:BenedettoAAlld:pubmed
pubmed-article:10079877pubmed:authorpubmed-author:MascellaniGGlld:pubmed
pubmed-article:10079877pubmed:authorpubmed-author:CellaiLLlld:pubmed
pubmed-article:10079877pubmed:authorpubmed-author:Di CaroAAlld:pubmed
pubmed-article:10079877pubmed:authorpubmed-author:MarzanoMMlld:pubmed
pubmed-article:10079877pubmed:authorpubmed-author:LiveraniLLlld:pubmed
pubmed-article:10079877pubmed:authorpubmed-author:BartoliniBBlld:pubmed
pubmed-article:10079877pubmed:authorpubmed-author:PerolaEElld:pubmed
pubmed-article:10079877pubmed:issnTypePrintlld:pubmed
pubmed-article:10079877pubmed:volume10lld:pubmed
pubmed-article:10079877pubmed:ownerNLMlld:pubmed
pubmed-article:10079877pubmed:authorsCompleteYlld:pubmed
pubmed-article:10079877pubmed:pagination33-8lld:pubmed
pubmed-article:10079877pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:10079877pubmed:meshHeadingpubmed-meshheading:10079877...lld:pubmed
pubmed-article:10079877pubmed:meshHeadingpubmed-meshheading:10079877...lld:pubmed
pubmed-article:10079877pubmed:meshHeadingpubmed-meshheading:10079877...lld:pubmed
pubmed-article:10079877pubmed:meshHeadingpubmed-meshheading:10079877...lld:pubmed
pubmed-article:10079877pubmed:meshHeadingpubmed-meshheading:10079877...lld:pubmed
pubmed-article:10079877pubmed:meshHeadingpubmed-meshheading:10079877...lld:pubmed
pubmed-article:10079877pubmed:meshHeadingpubmed-meshheading:10079877...lld:pubmed
pubmed-article:10079877pubmed:meshHeadingpubmed-meshheading:10079877...lld:pubmed
pubmed-article:10079877pubmed:meshHeadingpubmed-meshheading:10079877...lld:pubmed
pubmed-article:10079877pubmed:meshHeadingpubmed-meshheading:10079877...lld:pubmed
pubmed-article:10079877pubmed:meshHeadingpubmed-meshheading:10079877...lld:pubmed
pubmed-article:10079877pubmed:meshHeadingpubmed-meshheading:10079877...lld:pubmed
pubmed-article:10079877pubmed:year1999lld:pubmed
pubmed-article:10079877pubmed:articleTitleFractions of chemically oversulphated galactosaminoglycan sulphates inhibit three enveloped viruses: human immunodeficiency virus type 1, herpes simplex virus type 1 and human cytomegalovirus.lld:pubmed
pubmed-article:10079877pubmed:affiliationCentro di Virologia, IRCCS L Spallanzani, Roma, Italy.lld:pubmed
pubmed-article:10079877pubmed:publicationTypeJournal Articlelld:pubmed